Table 1.
Review of trials which studied the benefits of different blood pressure targets in patients older than 70 years of age
| Study (year) | The age of included population (years) | The average follow-up (years) | Study design | Number of patients | Conclusions |
|---|---|---|---|---|---|
| HYVET (2008) | >80 | 1.8 | Randomized controlled trial | 3845 | Control BP to <150/80 mmHg decreases fatal stroke, all-cause mortality, any cardiovascular events, and heart failure |
| VALISH (2010) | >70 | 3.07 | Randomized, open-label trial | 3260 | No difference was seen between strict (<140 mmHg) and mild control of BP (140-150 mmHg) in terms of composite cardiovascular diseases |
| Wei et al., (2013) | >70 | 4 | Randomized, open-label trial | 724 | Achieving BP <140/90 compared to BP <150/90 decreased total and cardiovascular mortality and reduced the rate of stroke |
| SPRINT (2016) | >75 | 3.14 | Randomized controlled trial | 2636 | Lower rates of cardiovascular events and death were seen with SBP target of <120 mmHg compared with an SBP target of <140 mmHg |
| Delgado et al., (2017) | >80 | 4.4 | Observational cohort analysis | 79,376 | The lowest mortality was observed in individuals with SBP of 135-154 mmHg |
HYVET: Hypertension in the Very Elderly Trial, VALISH: Valsartan in Elderly Isolated Systolic Hypertension, SPRINT: Systolic Blood Pressure Intervention Trial, SBP: Systolic blood pressure, BP: Blood pressure